LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response

Cancer Cell

Volumn 27, Issue 5, 2015, Pages 698-711

  Li, Fuming ^a   Han, Xiangkun ^a   Li, Fei ^a   Wang, Rui ^b   Wang, Hui ^c   Gao, Yijun ^a   Wang, Xujun ^d   Fang, Zhaoyuan ^a   Zhang, Wenjing ^a   Yao, Shun ^a   Tong, Xinyuan ^a   Wang, Yuetong ^a   Feng, Yan ^a   Sun, Yihua ^b   Li, Yuan ^b   Wong, Kwok Kin ^e   Zhai, Qiwei ^c   Chen, Haiquan ^b   Ji, Hongbin ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c Chinese Academy of Sciences   (China)

^d TONGJI UNIVERSITY   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; K RAS PROTEIN; PENTOSE PHOSPHATE; PROTEIN KINASE LKB1; REACTIVE OXYGEN METABOLITE; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE INACTIVATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; METABOLIC STRESS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OXIDATION REDUCTION REACTION; PENTOSE PHOSPHATE CYCLE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DISEASE MODEL; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MICE; OXIDATION-REDUCTION; PENTOSE PHOSPHATE PATHWAY; PROTEIN-SERINE-THREONINE KINASES; REACTIVE OXYGEN SPECIES;

EID: 84929294757     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.04.001     Document Type: Article

References (57)

1. Alessi D.R., Sakamoto K., Bayascas J.R. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 2006, 75:137-163.
2. Bardeesy N., Sinha M., Hezel A.F., Signoretti S., Hathaway N.A., Sharpless N.E., Loda M., Carrasco D.R., DePinho R.A. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002, 419:162-167.
3. Bruce C.R., Hoy A.J., Turner N., Watt M.J., Allen T.L., Carpenter K., Cooney G.J., Febbraio M.A., Kraegen E.W. Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 2009, 58:550-558.
4. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
5. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., Liu Y., Tupper T., Ouyang J., Li J., et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.
6. Chen Z., Fillmore C.M., Hammerman P.S., Kim C.F., Wong K.K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 2014, 14:535-546.
7. D'Autréaux B., Toledano M.B. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007, 8:813-824.
8. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
9. DuPage M., Dooley A.L., Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 2009, 4:1064-1072.
10. Farago A.F., Snyder E.L., Jacks T. SnapShot: lung cancer models. Cell 2012, 149. 246-246e1.
11. Foretz M., Ancellin N., Andreelli F., Saintillan Y., Grondin P., Kahn A., Thorens B., Vaulont S., Viollet B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005, 54:1331-1339.
12. Gan B., Hu J., Jiang S., Liu Y., Sahin E., Zhuang L., Fletcher-Sananikone E., Colla S., Wang Y.A., Chin L., Depinho R.A. Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 2010, 468:701-704.
13. Gao B., Sun Y., Zhang J., Ren Y., Fang R., Han X., Shen L., Liu X.Y., Pao W., Chen H., Ji H. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J. Thorac. Oncol. 2010, 5:1130-1135.
14. Gao Y., Xiao Q., Ma H., Li L., Liu J., Feng Y., Fang Z., Wu J., Han X., Zhang J., et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl. Acad. Sci. USA 2010, 107:18892-18897.
15. Gao Y., Zhang W., Han X., Li F., Wang X., Wang R., Fang Z., Tong X., Yao S., Li F., et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat. Commun. 2014, 5:4629.
16. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
17. Gurumurthy S., Xie S.Z., Alagesan B., Kim J., Yusuf R.Z., Saez B., Tzatsos A., Ozsolak F., Milos P., Ferrari F., et al. The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 2010, 468:659-663.
18. Han X., Li F., Fang Z., Gao Y., Li F., Fang R., Yao S., Sun Y., Li L., Zhang W., et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 2014, 5:3261.
19. Haq R., Shoag J., Andreu-Perez P., Yokoyama S., Edelman H., Rowe G.C., Frederick D.T., Hurley A.D., Nellore A., Kung A.L., et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 2013, 23:302-315.
20. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
21. Hardie D.G. The LKB1-AMPK pathway-friend or foe in cancer?. Cancer Cell 2013, 23:131-132.
22. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
23. Heist R.S., Engelman J.A. SnapShot: non-small cell lung cancer. Cancer Cell 2012, 21:448.e442.
24. Huang X., Wullschleger S., Shpiro N., McGuire V.A., Sakamoto K., Woods Y.L., McBurnie W., Fleming S., Alessi D.R. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 2008, 412:211-221.
25. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., Cho J., Suh J., Capelletti M., Sivachenko A., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
26. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
27. Jeon S.M., Chandel N.S., Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012, 485:661-665.
28. Ji H., Ramsey M.R., Hayes D.N., Fan C., McNamara K., Kozlowski P., Torrice C., Wu M.C., Shimamura T., Perera S.A., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448:807-810.
29. Kim H.S., Mendiratta S., Kim J., Pecot C.V., Larsen J.E., Zubovych I., Seo B.Y., Kim J., Eskiocak B., Chung H., et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 2013, 155:552-566.
30. Kuo W., Lin J., Tang T.K. Human glucose-6-phosphate dehydrogenase (G6PD) gene transforms NIH 3T3 cells and induces tumors in nude mice. Int. J. Cancer 2000, 85:857-864.
31. Liang M.C., Ma J., Chen L., Kozlowski P., Qin W., Li D., Goto J., Shimamura T., Hayes D.N., Meyerson M., et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene 2010, 29:1588-1597.
32. Mohseni M., Sun J., Lau A., Curtis S., Goldsmith J., Fox V.L., Wei C., Frazier M., Samson O., Wong K.K., et al. A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat. Cell Biol. 2014, 16:108-117.
33. Mukhopadhyay A., Berrett K.C., Kc U., Clair P.M., Pop S.M., Carr S.R., Witt B.L., Oliver T.G. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep. 2014, 8:40-49.
34. Nakada D., Saunders T.L., Morrison S.J. Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 2010, 468:653-658.
35. O'Connell M.P., Marchbank K., Webster M.R., Valiga A.A., Kaur A., Vultur A., Li L., Herlyn M., Villanueva J., Liu Q., et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 2013, 3:1378-1393.
36. Perl A.K., Wert S.E., Nagy A., Lobe C.G., Whitsett J.A. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl. Acad. Sci. USA 2002, 99:10482-10487.
37. Raj L., Ide T., Gurkar A.U., Foley M., Schenone M., Li X., Tolliday N.J., Golub T.R., Carr S.A., Shamji A.F., et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475:231-234.
38. Rekhtman N., Ang D.C., Sima C.S., Travis W.D., Moreira A.L. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod. Pathol. 2011, 24:1348-1359.
39. Salvemini F., Franzé A., Iervolino A., Filosa S., Salzano S., Ursini M.V. Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression. J. Biol. Chem. 1999, 274:2750-2757.
40. Schafer Z.T., Grassian A.R., Song L., Jiang Z., Gerhart-Hines Z., Irie H.Y., Gao S., Puigserver P., Brugge J.S. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
41. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
42. Shackelford D.B., Abt E., Gerken L., Vasquez D.S., Seki A., Leblanc M., Wei L., Fishbein M.C., Czernin J., Mischel P.S., Shaw R.J. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013, 23:143-158.
43. Shimamura T., Chen Z., Soucheray M., Carretero J., Kikuchi E., Tchaicha J.H., Gao Y., Cheng K.A., Cohoon T.J., Qi J., et al. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin. Cancer Res. 2013, 19:6183-6192.
44. Sporn M.B., Liby K.T. NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 2012, 12:564-571.
45. Sun Y., Ren Y., Fang Z., Li C., Fang R., Gao B., Han X., Tian W., Pao W., Chen H., Ji H. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J. Clin. Oncol. 2010, 28:4616-4620.
46. Sutherland K.D., Proost N., Brouns I., Adriaensen D., Song J.Y., Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011, 19:754-764.
47. Sutherland K.D., Song J.Y., Kwon M.C., Proost N., Zevenhoven J., Berns A. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2014, 111:4952-4957.
48. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
49. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
50. Tuveson D.A., Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene 1999, 18:5318-5324.
51. Vazquez F., Lim J.H., Chim H., Bhalla K., Girnun G., Pierce K., Clish C.B., Granter S.R., Widlund H.R., Spiegelman B.M., Puigserver P. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 2013, 23:287-301.
52. Wan X., Harkavy B., Shen N., Grohar P., Helman L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
53. Wang R., Pan Y., Li C., Zhang H., Garfield D., Li Y., Ye T., Hu H., Luo X., Li H., et al. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J. Thorac. Oncol. 2014, 9:760-768.
54. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
55. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathione metabolism and its implications for health. J. Nutr. 2004, 134:489-492.
56. Xu C., Fillmore C.M., Koyama S., Wu H., Zhao Y., Chen Z., Herter-Sprie G.S., Akbay E.A., Tchaicha J.H., Altabef A., et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014, 25:590-604.
57. Zaugg K., Yao Y., Reilly P.T., Kannan K., Kiarash R., Mason J., Huang P., Sawyer S.K., Fuerth B., Faubert B., et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011, 25:1041-1051.